Lapatinib and gemcitabine for metastatic pancreatic cancer: A phase II study

• DOI: 10.1200/jco.2009.27.15_suppl.e15653
• Publication Date: 2020-08-25T20:07:13Z
• Authors: H. Safran; T. Miner; N. Bahary; S. Whiting; C. Lopez; W. Sun; K. Charpentier; K. Charpentier; J. Shipley; E. Anderson; B. McNulty
• Keywords: Lapatinib; Regimen

e15653 Background: To determine the overall survival for patients with metastatic pancreatic cancer treated lapatinib and gemcitabine. Methods: Patients received lapatinib, 1,500 mg/day, Gemcitabine, 1 gm/m 2 /week 3 weeks followed by week off, until disease progression. This multicenter phase II study was planned to enter 125 evaluate if treatment regimen could achieve a 1-year of 30% median 7 months. An additional subset 20 were receive months single agent Results: At 6 month analysis, Brown University Oncology Group Data Safety Monitoring Board terminated accrual after 29 due futility analysis. The 4 (95% CI, 2.0–5.5 months). four who all progressed at month. Conclusions: Lapatinib is not effective in cancer. Evaluation HER2 inhibitors warranted. [Table: see text]